Hepatopulmonary syndrome;Le syndrome hépatopulmonaire

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 6-7, 2009, Pages 565-579

  Thevenot, T ^a   Pastor, C M ^b   Cervoni, J P ^a   Jacquelinet, C ^c   Nguyen Khac, E ^d   Richou, C ^a   Heyd, B ^a   Vanlemmens, C ^a   Mantion, G ^a   Di Martino, V ^a   Cadranel, J ^e  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Direction médicale et scientifique Agence de la biomédecine   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALMITRINE DIMESILATE; CEFTRIAXONE; CHLORAMPHENICOL; CYCLOPHOSPHAMIDE; ILOPROST; METHYLENE BLUE; METRONIDAZOLE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PREDNISONE; VANCOMYCIN;

BLOOD OXYGEN TENSION; CONTRAST ECHOCARDIOGRAPHY; DYSPNEA; GARLIC; HEPATOPULMONARY SYNDROME; HUMAN; HYPOXEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PROGNOSIS; SHORT SURVEY; SURGICAL MORTALITY; SURVIVAL RATE;

ANOXIA; BRONCHODILATOR AGENTS; ENZYME INHIBITORS; HEPATOPULMONARY SYNDROME; HUMANS; HYPERTENSION, PULMONARY; LIVER TRANSPLANTATION; MASS SCREENING; METHYLENE BLUE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PORTASYSTEMIC SHUNT, SURGICAL;

EID: 67649506215     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.03.013     Document Type: Short Survey

References (90)

1. Rodriguez-Roisin R., Krowka M.J., Herve P., and Fallon M.B. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 24 (2004) 861-880
2. Martinez G., Barbera J.A., Navasa M., Roca J., Visa J., and Rodriguez-Roisin R. Hepatopulmonary syndrome associated with cardiorespiratory disease. J Hepatol 30 (1999) 882-889
3. Krowka M.J. Hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. Clin Chest Med 26 (2005) 587-597
4. Gupta D., Vijaya D.R., Gupta R., Dhiman R.K., Bhargava M., Verma J., et al. Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroenterol 96 (2001) 3395-3399
5. Binay K., Sen S., Biswas P.K., Sanyal R., Jumdar D.M., and Biswas J. Hepatopulmonary obstruction responding to cavoplasty. Gastroenterology 118 (2000) 192-196
6. Regev A., Yeshurun M., Rodriguez M., Sagie A., Neff G.W., Molina E.G., et al. Transient hepatopulmonary syndrome in a patient with acute hepatitis A. J Viral Hepat 8 (2001) 83-86
7. Teuber G., Teupe C., Dietrich C.F., Caspary W.F., Buhl R., and Zeuzem S. Pulmonary dysfunction in non-cirrhotic patients with chronic viral hepatitis. Eur J Intern Med 13 (2002) 311-318
8. Herve P., Le Pavec J., Sztrymf B., Decante B., Savale L., and Sitbon O. Pulmonary vascular abnormalities in cirrhosis. Best Pract Res Clin Gastroenterol 21 (2007) 141-159
9. Gupta N.A., Abramowsky C., Pillen T., Redd D., Fasola C., Heffron T., et al. Pediatric hepatopulmonary syndrome is seen with polysplenia/interrupted inferior vena cava and without cirrhosis. Liver Transpl 13 (2007) 680-686
10. Barbe T., Losay J., Grimon G., Devictor D., Sardet A., Gautheir A., et al. Pulmonary arteriovenous shunting in children with liver disease. J Pediatr 126 (1995) 571-579
11. Battaglia S.E., Pretto J.J., Irving L.B., Jones R.M., and Angus P.W. Resolution of gas exchange abnormalities and intrapulmonary shunting following liver transplantation. Hepatology 25 (1997) 1228-1232
12. Kim B.J., Lee S.C., Park S.W., Choi M.S., Koh K.C., Paik S.W., et al. Characteristics and prevalence of intrapulmonary shunt detected by contrast echocardiography with harmonic imaging in liver transplant candidates. Am J Cardiol 94 (2004) 525-528
13. Martinez G.P., Barbera J.A., Visa J., Rimola A., Pare J.C., Roca J., et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 34 (2001) 651-657
14. Schenk P., Schoniger-Hekele M., Fuhrmann V., Madl C., Silberhumer G., and Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 125 (2003) 1042-1052
15. Krowka M.J., Dickson E.R., and Cortese D.A. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest 104 (1993) 515-521
16. Swanson K.L., Wiesner R.H., and Krowka M.J. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 41 (2005) 1122-1129
17. Gomez F.P., Martinez-Palli G., Barbera J.A., Roca J., Navasa M., and Rodriguez-Roisin R. Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. Hepatology 40 (2004) 660-666
18. Abrams G.A., Sanders M.K., and Fallon M.B. Utility of pulse oximetry in the detection of arterial hypoxemia in liver transplant candidates. Liver Transpl 8 (2002) 391-396
19. Pastor C.M., and Schiffer E. Therapy insight: hepatopulmonary syndrome and orthotopic liver transplantation. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 614-621
20. Zamirian M., Aslani A., and Shahrzad S. Left atrial volume: A novel predictor of hepatopulmonary syndrome. Am J Gastroenterol 102 (2007) 1392-1396
21. Abrams G.A., Nanda N.C., Dubovsky E.V., Krowka M.J., and Fallon M.B. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 114 (1998) 305-310
22. Arguedas M.R., Abrams G.A., Krowka M.J., and Fallon M.B. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 37 (2003) 192-197
23. Poterucha J.J., Krowka M.J., Dickson E.R., Cortese D.A., Stanson A.W., and Krom R.A. Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. Hepatology 21 (1995) 96-100
24. Zhang J., Ling Y., Luo B., Tang L., Ryter S.W., Stockard C.R., et al. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology 125 (2003) 1441-1451
25. Arguedas M.R., Drake B.B., Kapoor A., and Fallon M.B. Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology 128 (2005) 328-333
26. Oguro T., Takahashi Y., Ashino T., Takaki A., Shioda S., Horai R., et al. Involvement of tumor necrosis factor alpha, rather than interleukin-1alpha/beta or nitric oxides in the heme oxygenase-1 gene expression by lipopolysaccharide in the mouse liver. FEBS Lett 516 (2002) 63-66
27. Sztrymf B., Libert J.M., Mougeot C., Lebrec D., Mazmanian M., Humbert M., et al. Cirrhotic rats with bacterial translocation have higher incidence and severity of hepatopulmonary syndrome. J Gastroenterol Hepatol 20 (2005) 1538-1544
28. Rabiller A., Nunes H., Lebrec D., Tazi K.A., Wartski M., Dulmet E., et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 166 (2002) 514-517
29. Luo B., Liu L., Tang L., Zhang J., Ling Y., and Fallon M.B. ET-1 and TNF-alpha in HPS: analysis in prehepatic portal hypertension and biliary and nonbiliary cirrhosis in rats. Am J Physiol Gastrointest Liver Physiol 286 (2004) G294-303
30. Sztrymf B., Rabiller A., Nunes H., Savale L., Lebrec D., Le Pape A., et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J 23 (2004) 752-758
31. Luo B., Tang L., Wang Z., Zhang J., Ling Y., Feng W., et al. Cholangiocyte endothelin 1 and transforming growth factor beta1 production in rat experimental hepatopulmonary syndrome. Gastroenterology 129 (2005) 682-695
32. Ling Y., Zhang J., Luo B., Song D., Liu L., Tang L., et al. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology 39 (2004) 1593-1602
33. Rolla G., Brussino L., Colagrande P., Dutto L., Polizzi S., Scappaticci E., et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 26 (1997) 842-847
34. Nunes H., Lebrec D., Mazmanian M., Capron F., Heller J., Tazi K.A., et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 164 (2001) 879-885
35. Frossard J.L., Schiffer E., Cikirikcioglu B., Bourquin J., Morel D.R., and Pastor C.M. Opposite regulation of endothelial NO synthase by HSP90 and caveolin in liver and lungs of rats with hepatopulmonary syndrome. Am J Physiol Gastrointest Liver Physiol 293 (2007) G864-G870
36. Zhang J., Morrison J., Doeller J., Kraus D., Luo B., Tang L., et al. Evaluation of pulmonary hydrogen sulfide generation in experimental hepatopulmonary syndrome (abstract). Hepatology 46 Suppl. I (2007) A830
37. Fallon M.B., Roberts K., Krowka M.J., Shah V., Trotter J.F., Badesch D., et al. A multicenter case-control study of genetic predictors for hepatopulmonary syndrome (abstract). Hepatology 46 Suppl. I (2007) A41
38. Shijo H., Nakayama K., Sasaki H., Ueki T., Sakaguchi S., Sakata H., et al. Reversibility of pulmonary telangiectasia in liver cirrhosis evidenced by serial dynamic pulmonary perfusion imaging. Clin Nucl Med 14 (1989) 909-911
39. Saunders K.B., Fernando S.S., Dalton H.R., and Joseph A. Spontaneous improvement in a patient with the hepatopulmonary syndrome assessed by serial exercise tests. Thorax 49 (1994) 725-727
40. Swanson K.L., Wiesner R.H., and Krowka M.J. Long-term survival in hepatopulmonary syndrome (abstract). Chest 122 (2002) 210S-211S
41. Corpechot C., Barbu V., Wendum D., Kinnman N., Rey C., Poupon R., et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35 (2002) 1010-1021
42. Eriksson L.S., Söderman C., Ericzon B.G., Eleborg L., Wahren J., and Hedenstierna G. Normalization of ventilation/perfusion relationships after liver transplantation in patients with decompensated cirrhosis: evidence for a hepatopulmonary syndrome. Hepatology 12 (1990) 1350-1357
43. Lange P.A., and Stoller J.K. The hepatopulmonary syndrome. Effect of liver transplantation. Clin Chest Med 17 (1996) 115-123
44. Philit F., Wiesendanger T., Gille D., Boillot O., and Cordier J.F. Late resolution of hepatopulmonary syndrome after liver transplantation. Respiration 64 (1997) 173-175
45. Egawa H., Kasahara M., Inomata Y., Uemoto S., Asonuma K., Fujita S., et al. Long-term outcome of living related liver transplantation for patients with intrapulmonary shunting and strategy for complications. Transplantation 67 (1999) 712-717
46. Taille C., Cadranel J., Bellocq A., Thabut G., Soubrane O., Durand F., et al. Liver transplantation for hepatopulmonary syndrome: a ten-year experience in Paris, France. Transplantation 75 (2003) 1482-1489 1446-7 discussion
47. Krowka M.S., Mandell M.S., Ramsay M.A., Kawut S.M., Fallon M.B., Manzarbeitia C., et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 10 (2004) 174-182
48. Uemoto S., Inomata Y., Egawa H., Satomura K., Kiuchi T., Okajima H., et al. Effects of hypoxemia on early postoperative course of liver transplantation in pediatric patients with intrapulmonary shunting. Transplantation 63 (1997) 407-414
49. Krowka M.J., Porayko M.K., Plevak D.J., Pappas S.C., Steers J.L., Krom R.A., et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc 72 (1997) 44-53
50. Schiffer E., Majno P., Mentha G., Giostra E., Burri H., Klopfenstein C.E., et al. Hepatopulmonary syndrome increases the postoperative mortality rate following liver transplantation: a prospective study in 90 patients. Am J Transplant 6 (2006) 1430-1437
51. Shirakami G., Murakawa M., Shingu K., Mashima S., Suga S., Magaribuchi T., et al. Perioperative plasma concentrations of endothelin and natriuretic peptides in children undergoing living-related liver transplantation. Anesth Analg 82 (1996) 235-240
52. Meyers C., Low L., Kaufman L., Druger G., and Wong L.L. Trendelenburg positioning and continuous lateral rotation improve oxygenation in hepatopulmonary syndrome after liver transplantation. Liver Transpl Surg 4 (1998) 510-512
53. Durand P., Baujard C., Grosse A.L., Gomola A., Debray D., Dousset B., et al. Reversal of hypoxemia by inhaled nitric oxide in children with severe hepatopulmonary syndrome, type 1, during and after liver transplantation. Transplantation 65 (1998) 437-439
54. Murray K.F., and Carithers R.L. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 41 (2005) 1407-1432
55. Sulieman B., Voigt M.D., Katz D.A., and Hunsicker L.G. Data driven policy for points allocation in hepatopulmonary syndrome (abstract). Hepatology 42 (2005) 347A
56. Fallon M.B., Mulligan D.C., Gish R.G., and Krowka M.J. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transpl 12 (2006) S105-S107
57. Jones F.D., Kuo P.C., Johnson L.B., Njoku M.J., Dixon-Ferguson M.K., and Plotkin J.S. The coexistence of portopulmonary hypertension and hepatopulmonary syndrome. Anesthesiology 90 (1999) 626-629
58. Shah T., Isaac J., Adams D., and Kelly D. Development of hepatopulmonary syndrome and portopulmonary hypertension in a paediatric liver transplant patient. Pediatr Transplant 9 (2005) 127-131
59. Martinez-Palli G., and Barbera J.A. Severe portopulmonary hypertension after liver transplantation in a patient with preexisting hepatopulmonary syndrome. J Hepatol 31 (1999) 1075-1079
60. Ioachimescu O.C., Mehta A.C., and Stoller J.K. Hepatopulmonary syndrome following portopulmonary hypertension. Eur Respir J 29 (2007) 1277-1280
61. Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., and Venetos G. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67 (2000) 737-744
62. Brussino L., Bucca C., Morello M., Scappaticci E., Mauro M., and Rolla G. Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 362 (2003) 43-44
63. Gomez F.P., Barbera J.A., Roca J., Burgos F., Gistau C., and Rodriguez-Roisin R. Effects of nebulized N(G)-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. Hepatology 43 (2006) 1084-1091
64. Marczin N., Ryan U.S., and Catravas J.D. Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion. J Pharmacol Exp Ther 263 (1992) 170-179
65. Rolla G., Bucca C., and Brussino L. Methylene blue in the hepatopulmonary syndrome. N Engl J Med 331 (1994) 1098
66. Schenk P., Madl C., Rezaie-Majd S., Lehr S., and Müller C. Methylene blue improves the hepatopulmonary syndrome. Ann Int Med 133 (2000) 701-706
67. Peter C., Hongwan D., Küpfer A., and Lauterburg B.H. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 56 (2000) 247-250
68. Caldwell S.H., Jeffers L.J., Narula O.S., Lang E.A., Reddy K.R., and Schiff E.R. Ancient remedies revisited: does Allium sativum (garlic) palliate the hepatopulmonary syndrome?. J Clin Gastroenterol 15 (1992) 248-250
69. Abrams G.A., and Falon M.B. Treatment of hepatopulmonary syndrome with Allium sativum L, (garlic): a pilot trial. J Clin Gastroenterol 27 (1998) 232-235
70. Krug S., Seyfarth H.J., Hagendorff A., and Wirtz H. Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia. Eur J Gastroenterol Hepatol 19 (2007) 1140-1143
71. Allgaier H.P., Haag K., Ochs A., Hauenstein K.H., Jeserich M., Krause T., et al. Hepato-pulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol 23 (1995) 102
72. Riegler J.R., Lang K.A., Johnson S.P., and Westerman J.H. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology 109 (1995) 978-983
73. Corley D.A., Scharschmidt B., Bass B., Somberg K., and Gold W. Lack of efficacy of TIPS for hepatopulmonary syndrome. Gastroenterology 113 (1997) 728-730
74. Selim K.M., Akriviadis E.A., Zuckerman E., Chen D., and Reynolds T.B. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol 93 (1998) 455-458
75. Lasch H.M., Fried M.W., Zacks S.L., Odell P., Johnson M.W., Gerber D.A., et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome. Liver Transpl 7 (2001) 147-149
76. Paramesh A.S., Husain S.Z., Shneider B., Guller J., Tokat I., Gondolesi G.E., et al. Improvement of hepatopulmonary syndrome after transjugular intrahepatic portasystemic shunting: case report and review of literature. Pediatr Transplant 7 (2003) 157-162
77. Chevallier P., Noveli L., Motamedi J.P., Hastier P., Brunner P., and Bruneton J.N. Hepatopulmonary syndrome successfully treated with transjugular intrahepatic portosystemic shunt: a three-year follow-up. J Vasc Interv Radiol 15 (2004) 647-648
78. Martinez-Palli G., Drake B.B., Garcia-Pagan J.C., Barbera J.A., Arguedas M.R., and Rodriguez-Roisin R. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol 11 (2005) 6858-6862
79. De B.K., Sen S., and Sanyal R. Hepatopulmonary syndrome in noncirrhotic portal hypertension. Ann Intern Med 132 (2000) 924
80. Therapondos G., and Wong F. Miscellaneous indications for transjugular intrahepatic portosystemic stent-shunt. Eur J Gastroenterol Hepatol 18 (2006) 1161-1166
81. Van der Linden P., Le Moine O., Ghysels M., Ortinez M., and Devière J. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology 23 (1996) 982-987
82. Krowka M.J., and Cortese D.A. Hepatopulmonary syndrome. Current concepts in diagnostic and therapeutic considerations. Chest 105 (1994) 1528-1537
83. Song J.Y., Choi J.Y., Ko J.T., Bae E.J., Kim H.S., Noh C.I., et al. Long-term aspirin therapy for hepatopulmonary syndrome. Pediatrics 97 6 Pt 1 (1996) 917-920
84. Söderman C., Juhlin-Dannfelt A., Lagerstrand L., and Eriksson S. Ventilation-perfusion relationships and central haemodynamics in patients with cirrhosis. Effects of a somatostatin analogue. J Hepatol 21 (1994) 52-57
85. Cadranel J.L., Milleron B.J., Cadranel J.F., Fermand J.P., Andrivet P., and Brouet J.C. Severe hypoxemia-associated intrapulmonary shunt in a patient with chronic liver disease: improvement after medical treatment. Am Rev Respir Dis 146 (1992) 526-527
86. Krowka M.J., and Cortese D.A. Severe hypoxemia associated with liver disease: Mayo Clinic experience and the experimental use of almitrine bismesylate. Mayo Clin Proc 62 (1987) 164-173
87. Nakos G., Evreneglou D., Vassilakis N., and Lampropoulos S. Haemodynamics and gas exchange in liver cirrhosis: the effect of orally administered almitrine bismesylate. Respir Med 87 (1993) 93-98
88. Anel R.M., and Sheagren J.N. Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents. Clin Infect Dis 32 (2001) E131-E136
89. Agusti A.G., Roca J., Bosch J., Garcia-Pagan J.C., Wagner P.D., and Rodriguez-Roisin R. Effects of propranolol on arterial oxygenation and oxygen transport to tissues in patients with cirrhosis. Am Rev Respir Dis 142 (1990) 306-310
90. Wolfe J.D., Tashkin D.P., Holly F.E., Brachman M.D., and Genovesi M.G. Hypoxemia of cirrhosis: detection of abnormal small pulmonary vascular channels by a quantitative radionuclide method. Am J Med 63 (1977) 746-754